You searched for: spago nanomedical

Spago Nanomedical | Life Science Summit 2025

CEO Mats Hansen presents Spago Nanomedical at Life Science Summit 2025.

Spago Nanomedical decides on rights issue of SEK 25 million

Spago Nanomedical shows proof-of-concept for Tumorad

Spago’s CEO comments on Proof-of-Concept milestone

Spago Nanomedical has reported a positive outcome following the Data Monitoring Committee (DMC) review of the results to date in the...

Spago Nanomedical demonstrates tumor uptake in phase I/IIa study

Spago stays on schedule – green light for phase I/IIa study

Following a positive safety review, Spago Nanomedical's Phase I/IIa study has been granted permission to continue at the highest current dose level. The study is progressing...

Spago takes Tumorad-01 study to the next level

Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following...

Spago's CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”

2024 has marked a defining chapter for Spago Nanomedical, solidifying its position in radionuclide therapy. By focusing its energy...

Investing in life science: From Seed to Success 2024

Last week, investors and entrepreneurs gathered at the World Trade Center in Stockholm for "Investing in Life Science: From Seed...

Spago Nanomedical strengthened management to reflect project progress

The clinical phase I/IIa study evaluating radiopharmaceutical candidate 177Lu-SN201 in solid tumors has been progressing steadily for Spago Nanomedical....

Spago's CEO: Advancing the tumor program comes first

Spago Nanomedical's Q1 report signals steady progress with its radiopharma pipeline. Lead program Tumorad recently got a boost by...

Spago Nanomedical's CEO: “huge commercial opportunities are unfolding”

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of...